Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Safety of Clino-san on Vaginal Dryness of Breast Cancer Patients

This study has been completed.
Information provided by:
Seoul National University Hospital Identifier:
First received: February 4, 2008
Last updated: July 23, 2010
Last verified: July 2010
  1. Although after treatment for breast cancer such as chemotherapy or hormonal therapy, urogenital atrophy is common, the patients are seldomly treated for several reasons. Management of this problem is important for improving quality of life.
  2. "Clino-san" is a kind of vaginal lubricant with pH 5 which is similar pH of premenopausal vaginal discharge. After randomization of patients, they are treated with Clino-san or placebo 3 times/week for 12 weeks.
  3. We check the vaginal symptoms, vag dryness severity score, and ultrasonography at baseline, 4, 8, and 12 weeks of treatment.

Condition Intervention Phase
Breast Cancer
Vaginal Atrophy
Drug: clino-san vaginal lubricant
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Supportive Care
Official Title: Prospective Randomized Study on Efficacy and Safety of Clino-san® in the Management of Vaginal Dryness in Breast Cancer Patients

Resource links provided by NLM:

Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • vaginal dryness score [ Time Frame: for 12 weeks ]

Secondary Outcome Measures:
  • sexual dysfunction [ Time Frame: for 12 weeks ]

Enrollment: 98
Study Start Date: December 2007
Study Completion Date: February 2009
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Clino-san 2ml vaginal application 3 times per week for 12 weeks
Drug: clino-san vaginal lubricant
Clino-san 2ml vaginal application 3 times per week for 12 weeks
Placebo Comparator: 2
placebo 2ml vaginal application 3 times per week for 12 weeks
Drug: clino-san vaginal lubricant
Clino-san 2ml vaginal application 3 times per week for 12 weeks


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • breast cancer patients
  • who are treated with chemotherapy or hormonal therapy
  • who experience no menstruation after the previous therapy
  • who complain of vaginal dryness

Exclusion Criteria:

  • other cancer patients
  • other severe disease
  • poor compliance
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00607295

Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Seoul National University Hospital
Study Director: Jae Weon Kim, MD, PhD Seoul National University Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Yookyung Lee, Seoul National University Hospital Identifier: NCT00607295     History of Changes
Other Study ID Numbers: SNUH-OG-07-211
Study First Received: February 4, 2008
Last Updated: July 23, 2010

Keywords provided by Seoul National University Hospital:
hormonal therapy
urogenital atrophy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Pathological Conditions, Anatomical processed this record on May 24, 2017